What Do SAB Biotherapeutics Inc.'s Financial Risk Indicators Show?
| Indicator (fiscal 2025) | SAB Biotherapeutics Inc. | Peer median (same SIC code) | What it measures |
|---|---|---|---|
| Liabilities to assets | 12% | 33% | How much of the balance sheet is funded by obligations rather than equity. |
| Current ratio | 9.5x | 5.2x | Short-term assets per dollar of obligations due within a year. |
| Interest coverage | n/a | -8.7x | Operating income per dollar of interest expense. |
| Long-term debt to operating cash flow | n/a | 2.5x | Years of operating cash flow it would take to repay long-term debt. |
| Net debt | Not reported | n/a | Long-term debt minus cash; negative means more cash than long-term debt. |
The peer median uses 86 other companies in Swoopr's S&P 500 Equal Weight set that share the same SEC SIC code. A reading worse than the peer median is a prompt to read the filing, not a conclusion.
Where Are SAB Biotherapeutics Inc.'s Official Risk Factors?
The risks SAB Biotherapeutics Inc. considers material are disclosed in Item 1A of its Form 10-K, most recently filed March 9, 2026. Read them with three questions in mind: which risks are specific to this company rather than generic, which have changed since the prior year's filing, and which connect to the figures above (a refinancing risk matters more when interest coverage is thin).
Where These Numbers Come From
Every figure on this page is a value SAB Biotherapeutics Inc. reported in its own SEC filings, read from the SEC's XBRL data (accession 0001833214-26-000003 for fiscal year 2025). Ratios are computed from those reported values. Figures were retrieved on October 12, 2026; a later amendment or a new annual report can change them, and the filing itself always takes precedence over this summary.
Each fiscal year is labeled by the calendar year in which it ended, so a company that names the same period differently in its own filings (many retailers whose year ends in January) may use another label. A year is left out of the table when the SEC data set holds no value for it. A figure shown as "Not reported" means the company did not file a value under the standard tag Swoopr reads, not that the amount was zero. This page is educational and describes reported history only; it is not a forecast or a recommendation.
Frequently Asked Questions
Is SAB Biotherapeutics Inc. highly leveraged?
At the end of fiscal 2025, SAB Biotherapeutics Inc.'s total liabilities were 12% of total assets, against a peer median of 33%. Leverage that is normal for one industry (banks, utilities) can be high for another.
Where are SAB Biotherapeutics Inc.'s official risk factors?
In Item 1A, Risk Factors, of its annual report on Form 10-K, most recently filed with the SEC on March 9, 2026. The company lists the risks it considers material there; the measures on this page only quantify the financial side.
Can SAB Biotherapeutics Inc. pay its interest?
SAB Biotherapeutics Inc. did not report interest expense under the standard tags for fiscal 2025, so interest coverage is not computed here; its income statement and debt footnote show the details.